

Status: Currently Official on 14-Feb-2025  
Official Date: Official as of 01-May-2020  
Document Type: USP Monographs  
DocId: GUID-A5639E2E-13B3-48B4-9C13-671BAC2ECBAA\_3\_en-US  
DOI: https://doi.org/10.31003/USPNF\_M31690\_03\_01  
DOI Ref: 30tbq

© 2025 USPC  
Do not distribute

# Ethosuximide Oral Solution

## DEFINITION

Ethosuximide Oral Solution contains NLT 90.0% and NMT 105.0% of the labeled amount of ethosuximide ( $C_7H_{11}NO_2$ ).

## IDENTIFICATION

*Change to read:*

- A. ▲ **SPECTROSCOPIC IDENTIFICATION TESTS** (197), *Infrared Spectroscopy*: **197S** ▲ (CN 1-May-2020)

**Standard solution:** 30.0 mg/mL of [USP Ethosuximide RS](#) in [chloroform](#)

**Sample solution:** Nominally 30 mg/mL of ethosuximide in [chloroform](#) prepared as follows. Transfer the equivalent of about 150 mg of ethosuximide from Oral Solution to a 125-mL separatory funnel, add 50 mL of [ether](#), and shake well. Allow the layers to separate, and retain the ether layer. Wash the ether layer with three 10-mL portions of [water](#). Transfer the ether layer to a suitable beaker, add 5 g of [anhydrous sodium sulfate](#), and swirl. Filter the mixture into a 50-mL volumetric flask through a small pledget of cotton that has been previously washed with [ether](#). Evaporate to dryness. Dissolve the residue in 5 mL of [chloroform](#).

**Wavelength range:** 3000–1650  $cm^{-1}$

### Analysis

**Samples:** *Standard solution* and *Sample solution*

**Acceptance criteria:** Meets the requirements

- B. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

## ASSAY

*Change to read:*

### PROCEDURE

**Mobile phase:** [Acetonitrile](#) and [water](#) (12.5:87.5). To each liter, add 1.0 mL of [glacial acetic acid](#).

**System suitability solution:** 0.062 mg/mL of [USP Ethosuximide RS](#) and 0.064 mg/mL of [2-ethyl-2-methylsuccinic acid](#) in *Mobile phase*

**Standard solution:** 0.062 mg/mL of [USP Ethosuximide RS](#) in *Mobile phase*

**Sample solution:** Nominally 0.062 mg/mL of ethosuximide from Oral Solution in *Mobile phase* prepared as follows. Transfer a volume of Oral Solution, equivalent to 250 mg of ethosuximide, to a 100-mL volumetric flask. Dilute with *Mobile phase* to volume. Transfer 5.0 mL of this solution to a 200-mL volumetric flask and dilute with *Mobile phase* to volume.

### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 225 nm

**Column:** 3.9-mm × 15-cm; ▲ 4- $\mu m$  ▲ (USP 1-May-2019) packing L1

**Flow rate:** 1 mL/min

**Injection volume:** 10  $\mu L$

▲ **Run time:** NLT 2 times the retention time of ethosuximide ▲ (USP 1-May-2019)

### System suitability

**Sample:** *System suitability solution*

▲ [NOTE—The relative retention times for ethosuximide and 2-ethyl-2-methylsuccinic acid are 1.0 and 1.3, respectively.] ▲ (USP 1-May-2019)

### Suitability requirements

**Resolution:** NLT 3.5 between ethosuximide and 2-ethyl-2-methylsuccinic acid

**Tailing factor:** NMT 1.5

**Relative standard deviation:** NMT ▲ 1.0% ▲ (USP 1-May-2019) for ethosuximide and NMT 5.0% for 2-ethyl-2-methylsuccinic acid

### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of ethosuximide ( $C_7H_{11}NO_2$ ) in the portion of Oral Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

- $r_U$  = peak response from the *Sample solution*
- $r_S$  = peak response from the *Standard solution*
- $C_S$  = concentration of [USP Ethosuximide RS](#) in the *Standard solution* (mg/mL)
- $C_U$  = nominal concentration of ethosuximide in the *Sample solution* (mg/mL)

**Acceptance criteria:** 90.0%–105.0%

**IMPURITIES**

• **LIMIT OF 2-ETHYL-2-METHYLSUCCINIC ACID**

**Mobile phase, System suitability solution, Chromatographic system, and System suitability:** Proceed as directed in the Assay.

**Standard solution:** 0.05 mg/mL of [2-ethyl-2-methylsuccinic acid](#) in *Mobile phase*

**Sample solution:** Nominally 2.5 mg/mL of ethosuximide from Oral Solution in *Mobile phase* prepared as follows. Using a “to contain” pipet, transfer a volume of Oral Solution, equivalent to 250 mg of ethosuximide, to a 100-mL volumetric flask. Rinse the pipet several times with *Mobile phase*, and dilute with *Mobile phase* to volume.

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of 2-ethyl-2-methylsuccinic acid in the portion of Oral Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

- $r_U$  = peak response of 2-ethyl-2-methylsuccinic acid from the *Sample solution*
- $r_S$  = peak response of 2-ethyl-2-methylsuccinic acid from the *Standard solution*
- $C_S$  = concentration of 2-ethyl-2-methylsuccinic acid in the *Standard solution* (mg/mL)
- $C_U$  = nominal concentration of ethosuximide in the *Sample solution* (mg/mL)

**Acceptance criteria:** NMT 2.0%

**SPECIFIC TESTS**

- [pH \(791\)](#): 4.5–5.8

**ADDITIONAL REQUIREMENTS**

**Change to read:**

- **PACKAGING AND STORAGE:** Preserve in tight containers. ▲Store at controlled room temperature. Protect from freezing and light.▲ (USP 1-May-2019)
- [USP REFERENCE STANDARDS \(11\)](#).  
[USP Ethosuximide RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
ETHOSUXIMIDE ORAL SOLUTION	<a href="#">Documentary Standards Support</a>	SM42020 Small Molecules 4

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 44(1)

**Current DocID:** [GUID-A5639E2E-13B3-48B4-9C13-671BAC2ECBAA\\_3\\_en-US](#)

**DOI:** [https://doi.org/10.31003/USPNF\\_M31690\\_03\\_01](https://doi.org/10.31003/USPNF_M31690_03_01)

**DOI ref:** [30tbq](#)